LCTX Company Profile and Key Details

Q: Who are the executives of LCTX?

Mr. William Annett MBAPres & Chief Executive Officer of OncoCyte CorporationMr. George A. Samuel III, J.D.Gen. Counsel & Company Sec.Dr. Rami SkaliterChief Executive Officer of Cell Cure Neurosciences Ltd.Mr. Brian M. Culley M.A., M.B.A.Chief Executive Officer, Pres & DirectorDr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.Senior Vice President of Clinical & Medical AffairsMs. Alexandra HernandezSenior Director of Fin. & ControllerDr. Harold D. WaitzVice President of Regulatory Affairs & Quality ControlMs. Jill Ann HoweChief Financial Officer & Principal Financial and Accounting OfficerIoana C. HoneDirector of Investor Relations

AMEX : LCTX

Lineage Cell Therapeutics

$1.51

0.05+3.42%

At Close 4:00 PM

67.36

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Lineage Cell Therapeutics, Inc. (LCTX) stock surged +1.32%, trading at $1.53 on AMEX, up from the previous close of $1.51. The stock opened at $1.50, fluctuating between $1.49 and $1.55 in the recent session.

Stock Snapshot

1.51

Prev. Close

381.1M

Market Cap

1.49

Day Low

-5.46

P/E Ratio

-0.28

EPS (TTM)

-0.17

Cash Flow per Share

1.5

Open

249.09M

Number of Shares

1.55

Day High

99.56%

Free Float in %

0.37

Book Value

1.36M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	1.46	1.52	1.46	1.51	1.83M
Apr 29, 2026	1.58	1.58	1.46	1.46	2.27M
Apr 28, 2026	1.56	1.66	1.53	1.56	1.31M
Apr 27, 2026	1.56	1.60	1.54	1.55	611.75K
Apr 23, 2026	1.64	1.66	1.54	1.56	1.05M
Apr 22, 2026	1.67	1.69	1.62	1.63	433.75K
Apr 21, 2026	1.67	1.68	1.62	1.64	846.1K
Apr 20, 2026	1.70	1.70	1.65	1.65	876.07K
Apr 17, 2026	1.65	1.75	1.64	1.71	1.98M
Apr 16, 2026	1.63	1.64	1.56	1.64	862.08K
Apr 14, 2026	1.55	1.60	1.55	1.59	760.72K
Apr 13, 2026	1.46	1.53	1.45	1.51	927.42K
Apr 10, 2026	1.51	1.53	1.46	1.48	846.58K
Apr 09, 2026	1.52	1.56	1.49	1.49	991.3K
Apr 08, 2026	1.63	1.65	1.54	1.54	1.21M
Apr 07, 2026	1.52	1.56	1.50	1.52	1.04M
Apr 06, 2026	1.54	1.60	1.52	1.54	1.24M
Apr 02, 2026	1.56	1.61	1.54	1.56	581.55K
Apr 01, 2026	1.62	1.63	1.57	1.59	781.11K
Mar 31, 2026	1.48	1.60	1.47	1.58	1.02M

Contact Details

Carlsbad, CA 92008

United States

https://www.lineagecell.com 442 287 8990

About Company

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Stock Peers

TBXU

1.0015+3.51%

Direxion Daily Biotech Top 5 Bull 2X ETF$29.53 PTHS

-0.09-0.36%

Pelthos Therapeutics Inc.$25.00 PTN

-0.06-0.30%

Palatin Technologies, Inc.$20.21 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 ARMP

0.43+4.50%

Armata Pharmaceuticals, Inc.$9.98 CYBN

0.1+1.22%

Cybin Inc.$8.28 NRXS

0.01+0.13%

NeurAxis, Inc.$7.45 CANF

0.2+6.69%

Can-Fite BioPharma Ltd.$3.19 CVM

0.16+5.50%

CEL-SCI Corporation$3.07 NSRX

0.14+5.47%

Nasus Pharma Ltd.$2.70

Company Overview

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) closed at $1.53 USD, gaining $0.02 (1.32%) from the previous close of $1.51. The stock is currently mid-range between its 52-week high and low $0.43 and $2.09. With a market capitalization of about $381.10 million, Lineage Cell Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.80). Key stats such as the average daily volume over the past year has been around 1.19 million shares, in line with its 52-week average. Headquartered in Carlsbad, CA, Lineage Cell Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brian Culley, the company employs approximately 70 people and listed since March 05, 1992. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 13.36%, SMA50 15.16%, SMA200 42.23%). The stock’s 14-day RSI is 65.02 (firm momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.22% below its high and over 436.84% above its low. Average 10-day trading volume of 1.25 million shares is in line with the 3-month average of 1.17 million, indicating normal recent market interest.

Valuation Metrics

Lineage Cell Therapeutics, Inc. trades at a P/E ratio of -5.45, slightly below the S&P 500 average, with a price-to-sales ratio of 25.75 and a price-to-book ratio of 7.77 trading at moderately above to book value. The P/FCF stands at -19.57, also below market averages.

Dividend & Fair Value

Lineage Cell Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.33. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Lineage Cell Therapeutics, Inc. generated EPS of -$0.30 over the past year. Five-year average earnings growth is -2.93%. Wall Street analysts project EPS growth of 2.53% annually over the next five years. The latest quarter delivered EPS of $0.00. The next quarter is forecast at -$0.04. Next year's EPS is expected at $10.53. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $2.00. The high target offers 496.03% upside. The low target suggests 32.45% downside. The mean target is $4.58. This offers 203.31% upside. Lineage Cell Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 05, 2026, missed forecasts by -109.23%. The prior quarter beat by 550.0%. Over the last six quarters, Apple has recorded several small beats. These include 53.49% in November 14, 2024.

Shareholding & Insider Activity

Lineage Cell Therapeutics, Inc. has 228.36 million shares outstanding. The public float is 177.83 million shares, elevated short interest at 21.29% of float. This equals 27.24 million shares. The short ratio is 13.87 days. Institutional investors hold 42.95% of the float. Insiders own 0.42%. BRADSHER NEAL C holds 34.27 million shares, BROADWOOD PARTNERS LP has 24.90 million shares and BROADWOOD PARTNERS, L.P. has 7.89 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Lineage Cell Therapeutics generated $8.95M in revenue, or $0.05 per share. Gross margin was 84.76%, operating margin -276.50%, and net profit margin -240.20%. Returns are negative, with ROA at -21.27% and ROE at -33.88%.
On valuation metrics, Lineage Cell Therapeutics trades at a P/E of -5.45, P/S of 25.75 and P/B of 7.77. The current ratio is 5.20 and quick ratio is 5.20. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -972.03 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.05, supported by a cash flow-to-debt ratio of -7.82.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Lineage Cell Therapeutics posted revenue of $8.95M, down slightly from $14.70M in the prior quarter. Gross profit was $7.58M (margin 84.76%). Operating income was - $24.73M (margin -276.5%). Net income was- $21.49M (EPS - $0.12).
The company ended the quarter with $35.49M in cash and short-term investments, a total debt of $2.95M, and net debt of - $32.49M. Total assets were $101.02M, with equity of $62.02M. Financials further reflected weakness, with operating cash flow of - $28.57M, free cash flow of - $29.24M, and capital expenditures of - $674.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Lineage Cell Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 127.81%, reaching $3.44 by July 29, 2026, with a range of $3.40 to $3.47. 1-Year Outlook: Projected gain of 1106.62%, with price at $18.22 by April 30, 2027, within a range of $19.58 to $21.83.

Key Takeaways

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) shares are flat -1.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been flat over the last quarter, despite recent volatility. Valuation shows Lineage Cell Therapeutics, Inc. trading at a premium to the broader market with a P/E of -5.45. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.23, suggesting 246.36% upside.

Frequently Asked Questions

What is the current Lineage Cell Therapeutics, Inc. (LCTX) stock price?

Lineage Cell Therapeutics, Inc. (AMEX: LCTX) stock price is $1.53 in the last trading session. During the trading session, LCTX stock reached the peak price of $1.55 while $1.49 was the lowest point it dropped to. The percentage change in LCTX stock occurred in the recent session was 1.32% while the dollar amount for the price change in LCTX stock was $0.02.

LCTX's industry and sector of operation?

The AMEX listed LCTX is part of Biotechnology industry that operates in the broader Healthcare sector. Lineage Cell Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of LCTX?

Mr. William Annett MBA
Pres & Chief Executive Officer of OncoCyte Corporation
Mr. George A. Samuel III, J.D.
Gen. Counsel & Company Sec.
Dr. Rami Skaliter
Chief Executive Officer of Cell Cure Neurosciences Ltd.
Mr. Brian M. Culley M.A., M.B.A.
Chief Executive Officer, Pres & Director
Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.
Senior Vice President of Clinical & Medical Affairs
Ms. Alexandra Hernandez
Senior Director of Fin. & Controller
Dr. Harold D. Waitz
Vice President of Regulatory Affairs & Quality Control
Ms. Jill Ann Howe
Chief Financial Officer & Principal Financial and Accounting Officer
Ioana C. Hone
Director of Investor Relations

How LCTX did perform over past 52-week?

LCTX's closing price is 251.16% higher than its 52-week low of $0.43 where as its distance from 52-week high of $2.09 is -27.75%.

How many employees does LCTX have?

Number of LCTX employees currently stands at 70.

Link for LCTX official website?

Official Website of LCTX is: https://www.lineagecell.com

How do I contact LCTX?

LCTX could be contacted at phone 442 287 8990 and can also be accessed through its website. LCTX operates from 2173 Salk Avenue, Carlsbad, CA 92008, United States.

How many shares of LCTX are traded daily?

LCTX stock volume for the day was 1.36M shares. The average number of LCTX shares traded daily for last 3 months was 1.19M.

What is the market cap of LCTX currently?

The market value of LCTX currently stands at $381.10M with its latest stock price at $1.53 and 249.09M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	70
Beta	1.76
Sales or Revenue	$8.95M
5Y Sales Change%	3.643%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

LCTX Company Profile and Key Details

Lineage Cell Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics